16 September 2026 editorial review · Trial
TN-22: Hydroxychloroquine in stage 1 at-risk individuals: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Retained futility result and secondary immune findings; qualified categorical safe claim to observed trial follow-up.
Registry: NCT03428945. Registered endpoint checked: Change From Treatment Assignment Glucose Tolerance to Abnormal Glucose Tolerance or Diabetes (Glucose tolerance is measured every 6 months for up to 4 years). Eligibility check: Registry age 3 Years to not specified; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Accessible primary literature: Hydroxychloroquine in Stage 1 Type 1 Diabetes.. Limits: Primary abstract findings were available; supplementary tables and full adverse-event adjudication were not comprehensively re-reviewed. Registry eligibility is not a claim of current site availability.